Biomarker solutions to accelerate global clinical trials

Molecular Insights— base by base, from target discovery to commercial launch.

We are applying our expertise in genomic profiling to identify elusive cancer-related genetic changes and new biomarker targets across many cancer types. Our advanced cancer genome analysis helps researchers and biopharmaceutical partners accelerate new precision medicine development.

Comprehensive support for biomarker-driven drug development

We support genomic profiling of Phase I-III clinical trial samples in our CLIA-certified and CAP-accredited laboratories utilizing our panel of comprehensive molecular profiling assays.

CLINICAL APPLICATIONS

Liquid biopsy for treatment selection, disease monitoring, and MRD detection

Molecular profiling assays

One panel does not fit all

We offer a portfolio of comprehensive genomic profiling assays for precision medicine development.

Immuno-oncology and biomarker solutions

  • TMB
  • MSI
  • PDL1 (CNV, SV)
PredicineATLAS™

DNA damage repair and clinical solutions

  • BRCA1/2
  • ATM
  • FGFR1/2/3/4
PredicineCARE™

Fusion and splicing RNA solutions

  • NTRK1/2/3
  • AR
  • MET
PredicineRNA™

Our Comprehensive Product Portfolio

Compare our assays

COMPAREPredicineATLAS™PredicineCARE™PredicineRNA™PredicineHEREDITARY™
OVERVIEWBroadest liquid biopsy panelFocused pan-cancer panel that includes guideline-recommended genes Panel for known or novel gene fusion / splice variant detectionPanel that analyzes genes associated with hereditary cancers
NUMBER OF GENES600 (DNA)152 (DNA)88 (RNA)25 (DNA)
SPECIMEN TYPEBlood
Urine
Tissue
Blood
Urine
Tissue
Blood
Tissue
Blood
TURNAROUND TIME10 Days10 Days10 Days10 Days
MUTATIONSSomaticSomaticSomaticGermline
TMB
MSI
MMR
HRD
REPORT FEATURESPoint mutations, insertions/deletions, copy number gain, copy number loss, rearrangements Point mutations, insertions/deletions, copy number gain, copy number loss, rearrangements RNA fusions
RNA splice variants
Pathogenic germline variants
SEQUENCE COVERAGE20,000x20,000x 100x
SENSITIVITY0.25% down to 0.05%0.25% down to 0.05%10 copies20%
ADDITIONAL NOTESCLIA
RUO
CLIA
RUO
RUOCLIA
RUO
DETAILSAbout PredicineATLAS™ About PredicineCARE™About PredicineRNA™About PredicineHEREDITARY™

CROSS-BORDER TRIALS

Harmonized assay in U.S. and China for global clinical trials

We provide harmonized assays supported by unified quality management systems and workflow in our network of CLIA-certified and CAP-accredited facilities in U.S. and China to support cross-border clinical studies.

Get in touch

Ready to streamline your precision oncology clinical research programs? Submit your information to speak to a team member.